TNFSF13 and myalgic encephalomeyelitis/chronic fatigue syndrome: APRIL was not significantly influenced either by the ME/CFS disease itself (no difference in serum APRIL levels at baseline from healthy controls) or by the intervention (rituximab versus placebo).